1094873-17-2

1094873-17-2 structure

Name: (R)-JNJ-31020028
Chemical Name: N-(4-{4-[(1R)-2-(Diethylamino)-2-oxo-1-phenylethyl]-1-piperazinyl}-3-fluorophenyl)-2-(3-pyridinyl)benzamide
CAS Number: 1094873-17-2
Molecular Formula: C₃₄H₃₆FN₅O₂
Molecular Weight: 565.680
Catalog: Signaling Pathways GPCR/G Protein Neuropeptide Y Receptor
Create Date: 2018-07-06 08:15:20
Modify Date: 2024-01-10 10:06:54
(R)-JNJ-31020028 is a high affinity, selective brain penetrant neuropeptide Y Y2 receptor antagonist, with pIC50 values of 8.07, 8.22 and 8.21 for human, rat, and mouse Y2 receptor, respectively. (R)-JNJ-31020028 shows >100-fold selective versus human Y1, Y4, and Y5 receptors. (R)-JNJ-31020028 has antidepressant like effects[1][2].

Name	N-(4-{4-[(1R)-2-(Diethylamino)-2-oxo-1-phenylethyl]-1-piperazinyl}-3-fluorophenyl)-2-(3-pyridinyl)benzamide
Synonyms	1-Piperazineacetamide, N,N-diethyl-4-[2-fluoro-4-[[2-(3-pyridinyl)benzoyl]amino]phenyl]-α-phenyl-, (αR)- N-(4-{4-[(1R)-2-(Diethylamino)-2-oxo-1-phenylethyl]-1-piperazinyl}-3-fluorophenyl)-2-(3-pyridinyl)benzamide MFCD29477347

Description	(R)-JNJ-31020028 is a high affinity, selective brain penetrant neuropeptide Y Y2 receptor antagonist, with pIC50 values of 8.07, 8.22 and 8.21 for human, rat, and mouse Y2 receptor, respectively. (R)-JNJ-31020028 shows >100-fold selective versus human Y1, Y4, and Y5 receptors. (R)-JNJ-31020028 has antidepressant like effects[1][2].
Related Catalog	Research Areas >> Neurological Disease Signaling Pathways >> GPCR/G Protein >> Neuropeptide Y Receptor
Target	human Y2 receptor:8.07 (pIC50) rat Y2 receptor:8.22 (pIC50) mouse Y2 receptor:8.21 (pIC50)
In Vivo	(R)-JNJ-31020028 (5.6 μg; chronic icv infusion; daily for 10 days) has antidepressant like effects in the olfactory bulbectomized rat (OBX) model[1]. Chronic icv administration of (R)-JNJ-31020028 at 5.6 μg/day using osmotic Alzet pump resulted in a significant decreases number of grooming events[1]. (R)-JNJ-31020028 treatment shows the Cmax, Tmax , AUCinf, Vd, and t1/2 were 4.35 μM, 0.5 hours, 7.91 h μM and 0.83 hours, respectively[1]. Animal Model: Male Sprague Dawley rats weighing 150-170 (OBX model)[1] Dosage: 5.6 μg Administration: chronic icv infusion; daily for 10 days Result: Reduced OBX rat immobility time. Animal Model: male Sprague-Dawley rat[2] Dosage: 10 mg/kg Administration: s.c. (Pharmacokinetic Analysis) Result: The Cmax, Tmax , AUCinf, Vd, and t1/2 were 4.35 μM, 0.5 hours, 7.91 h μM and 0.83 hours, respectively.
References	[1]. Shoblock JR, et al. In vitro and in vivo characterization of JNJ-31020028 (N-(4-{4-[2-(diethylamino)-2-oxo-1-phenylethyl]piperazin-1-yl}-3-fluorophenyl)-2-pyridin-3-ylbenzamide), a selective brain penetrant small molecule antagonist of the neuropeptide Y Y(2) receptor. Psychopharmacology (Berl). 2010 Feb;208(2):265-77. [2]. Morales-Medina JC, et al. Chronic administration of the Y2 receptor antagonist, JNJ-31020028, induced anti-depressant like-behaviors in olfactory bulbectomized rat. Neuropeptides. 2012 Dec;46(6):329-34.

Density	1.2±0.1 g/cm3
Boiling Point	677.5±55.0 °C at 760 mmHg
Molecular Formula	C₃₄H₃₆FN₅O₂
Molecular Weight	565.680
Flash Point	363.5±31.5 °C
Exact Mass	565.285278
LogP	5.23
Vapour Pressure	0.0±2.1 mmHg at 25°C
Index of Refraction	1.628

1094873-17-2	1094873-14-9
1391481-68-7	73981-53-0
1391485-18-9	66423-07-2
1213878-29-5	528566-21-4
2242647-55-6	1640848-93-6